Melanoma Trials in Grenoble, France
Conditions / Melanoma / Grenoble, France
Melanoma has been the subject of sustained clinical investigation across multiple research sites.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | COMPLETED | — |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO | RECRUITING | PHASE3 |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma | COMPLETED | PHASE3 |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma | COMPLETED | PHASE3 |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | TERMINATED | PHASE3 |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | TERMINATED | PHASE3 |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma | TERMINATED | PHASE3 |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | COMPLETED | PHASE3 |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | TERMINATED | PHASE3 |